Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. The company's products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. In addition, it provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of NPX data. Olink Holding AB (publ) sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. The company was founded in 2004 and is headquartered in Uppsala, Sweden. Olink Holding AB (publ) is a subsidiary of Summa Equity Holding AB.
IPO Year: 2021
Exchange: NASDAQ
Website: https://www.olink.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/5/2023 | $27.00 | Sector Outperform | Scotiabank |
| 12/14/2022 | $28.00 | Buy | Canaccord Genuity |
| 2/14/2022 | $33.00 → $32.00 | Equal-Weight | Morgan Stanley |
This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail. UPPSALA, Sweden, July 11, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the "Company"), reg. no. 559189-7755, are hereby given notice to attend the Extra General Meeting to be held at 4:00 p.m. CEST on Tuesday 6 August 2024, in the Company's facilities at Salagatan 16F, Uppsala. Registration for the meeting commences at 3:30 p.m. CEST. NOTICE OF PARTICIPATION Shareholders who wish to attend in the proceedings of the Extra General Meeting must: be entered in the share register kept on behalf of the Company by Eur
Subsequent Offering Period Scheduled to Expire at 5:00 p.m., New York Time, on July 16, 2024 Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher"), the world leader in serving science, today announced that it has completed its acquisition of Olink Holding AB (publ) ("Olink") (NASDAQ:OLK), a leading provider of next-generation proteomics solutions. The transaction values Olink at approximately $3.1 billion, net of $96 million of acquired cash. Olink will become part of Thermo Fisher's Life Sciences Solutions segment. "We are excited to welcome Olink colleagues to Thermo Fisher," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. "Protein research
UPPSALA, Sweden, July 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced that the UK Competition and Markets Authority (the "CMA") has unconditionally approved the previously announced tender offer (the "Offer") by Orion Acquisition AB (the "Buyer"), a wholly owned subsidiary of Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher" or "Parent"), for all outstanding Common Shares and American Depositary Shares (together, the "Shares") of Olink for $26.00 per Share. The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink. As a result of the CMA approval, Olink and Thermo Fis
UPPSALA, Sweden, July 05, 2024 (GLOBE NEWSWIRE) -- At the Extra General Meeting (the "EGM") of Olink Holding AB (publ), reg. no 559189-7755, (the "Company"), the EGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the EGM and the complete proposals, which have previously been published and are available on the Company's website, www.olink.com. Resolution on compensation to the board of directorsThe EGM resolved, in accordance with the majority shareholder's proposal, to grant each board member compensation in addition to the compensation resolved by the annual general meeting. This addit
UPPSALA, Sweden, July 03, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (NASDAQ:OLK), a global leader in proteomics, introduces its inaugural network of Olink® Certified Service Providers. The group of Olink Certified Service Providers represent leading contract research organizations (CROs) and service labs around the world. Cutting-Edge Technology, Commitment to ExcellenceTo become an Olink Certified Service Provider, each organization must undergo training, annual concordance testing, and re-certification to demonstrate their ability to consistently perform Olink workflows with the highest quality. By combining their expertise with Olink's next-generation proteomics solutions, resea
This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail. UPPSALA, Sweden, June 11, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the "Company"), reg. no. 559189-7755, are hereby given notice to attend the Extra General Meeting to be held at 4:00 p.m. CET on Friday 5 July 2024, in the Company's facilities at Salagatan 16A, Uppsala. Registration for the meeting commences at 3:30 p.m. CET. NOTICE OF PARTICIPATION Shareholders who wish to attend in the proceedings of the Extra General Meeting must: be entered in the share register kept on behalf of the Company by Eu
UPPSALA, Sweden, June 06, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (NASDAQ:OLK) today announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research. More Confidence, More Insights, Less Sample Biomarker selection for Olink Target 48 Immune Surveillance were designed to give researchers the most effective platform for detecting and quantifying up to 44 well-established biomarkers across key immunological processes in as little as 1μL of sample. When combined with the Olink Target 48 Cytokine panel, scient
UPPSALA, Sweden, May 30, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (NASDAQ:OLK) today reported the publication of a landmark study using the Olink Explore platform to identify proteins in the blood that may provide a 7-year warning for various cancers. The findings, published in Nature Communications, illustrate the tremendous potential of proteomics to revolutionize cancer detection, allowing for intervention at much earlier stages, potentially leading to better treatment outcomes and even prevention. Early Detection – A Game Changer. In the groundbreaking work, conducted by Oxford Population Health and funded by Cancer Research UK, researchers describe how they used Olink's ne
UPPSALA, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced its unaudited financial results for the first quarter ended March 31, 2024. Highlights First quarter 2024 revenue totaled $28.8 million, representing year over year growth of 5% on a reported basis and 5% on a constant currency adjusted like-for-like basisTotal Explore customer installations reached 121, with 14 installations during the first quarterTotal Signature Q100 placements reached 202, with 16 placements during the first quarterExplore revenue of $18.0 million accounted for 63% of total first quarter revenue, with Explore Kit revenue totaling $11.3 million, or 63% of t
UPPSALA, Sweden, April 19, 2024 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the "AGM") of Olink Holding AB (publ), reg. no 559189-7755, (the "Company"), on 19 April 2024 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company's website, www.olink.com. Adoption of the balance sheet and income statement, disposition regarding the Company's results and discharge from liabilityThe AGM adopted the Company's income statement and balance sheet and the consolidated income statement an
Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4
Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company's Board of Directors. As the former Corporate Vice President for Microsoft, leading global health and life sciences, Dr. Moore brings extensive experience and expertise in integrating R&D, AI and machine learning, and cloud and data technologies to positively transform companies within the health and life sciences ecosystem. "Greg is an industry leader, driving technology and life sciences innovation at the intersection of medical and large-scale computation," said Stephen Berenson, Chairman of Cellar
UPPSALA, Sweden, March 21, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced the appointment of life sciences industry veteran Bruno Rossi to the role of Chief Commercial Officer (CCO), effective immediately. Mr. Rossi will lead the Company's global commercial organization including Sales, Marketing and Sales Operations. He will report to Carl Raimond, President of Olink. "I am delighted to welcome Bruno to the Olink organization, and look forward to the value his considerable industry experience will add to our rapidly growing company." said Carl Raimond, President of Olink. "Over the past two years, Olink has experienced remarkable growth. We have a
15F-12B - Olink Holding AB (publ) (0001835539) (Filer)
6-K - Olink Holding AB (publ) (0001835539) (Filer)
SC 14D9/A - Olink Holding AB (publ) (0001835539) (Subject)
SC TO-T/A - Olink Holding AB (publ) (0001835539) (Subject)
6-K - Olink Holding AB (publ) (0001835539) (Filer)
6-K - Olink Holding AB (publ) (0001835539) (Filer)
S-8 POS - Olink Holding AB (publ) (0001835539) (Filer)
S-8 POS - Olink Holding AB (publ) (0001835539) (Filer)
S-8 POS - Olink Holding AB (publ) (0001835539) (Filer)
S-8 POS - Olink Holding AB (publ) (0001835539) (Filer)
Scotiabank initiated coverage of Olink Holding with a rating of Sector Outperform and set a new price target of $27.00
Canaccord Genuity initiated coverage of Olink Holding with a rating of Buy and set a new price target of $28.00
Morgan Stanley reiterated coverage of Olink Holding with a rating of Equal-Weight and set a new price target of $32.00 from $33.00 previously
SC 13G/A - Olink Holding AB (publ) (0001835539) (Subject)
SC 13G - Olink Holding AB (publ) (0001835539) (Subject)
SC 13G/A - Olink Holding AB (publ) (0001835539) (Subject)
SC 13G/A - Olink Holding AB (publ) (0001835539) (Subject)
SC 13G/A - Olink Holding AB (publ) (0001835539) (Subject)
SC 13G/A - Olink Holding AB (publ) (0001835539) (Subject)
SC 13G/A - Olink Holding AB (publ) (0001835539) (Subject)
SC 13G/A - Olink Holding AB (publ) (0001835539) (Subject)
SC 13G - Olink Holding AB (publ) (0001835539) (Subject)
SC 13G - Olink Holding AB (publ) (0001835539) (Subject)
UPPSALA, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced its unaudited financial results for the first quarter ended March 31, 2024. Highlights First quarter 2024 revenue totaled $28.8 million, representing year over year growth of 5% on a reported basis and 5% on a constant currency adjusted like-for-like basisTotal Explore customer installations reached 121, with 14 installations during the first quarterTotal Signature Q100 placements reached 202, with 16 placements during the first quarterExplore revenue of $18.0 million accounted for 63% of total first quarter revenue, with Explore Kit revenue totaling $11.3 million, or 63% of t
UPPSALA, Sweden, April 19, 2024 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the "AGM") of Olink Holding AB (publ), reg. no 559189-7755, (the "Company"), on 19 April 2024 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company's website, www.olink.com. Adoption of the balance sheet and income statement, disposition regarding the Company's results and discharge from liabilityThe AGM adopted the Company's income statement and balance sheet and the consolidated income statement an
UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023. Highlights Fourth quarter 2023 revenue totaled $68.6 million, representing year over year growth of 18% on a reported basis and 17% on a constant currency adjusted like-for-like basisFull year revenue 2023 revenue totaled $169.6 million, achieving year over year growth of 21% on a reported basis and 21% on a constant currency adjusted like-for-like basisTotal Explore customer installations reached 107, with 20 installations during the fourth quarterTotal Signature Q100 placements reached 186, wit
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter and Full Year 2023 Highlights Fourth quarter revenue was $10.89 billion, 5% lower versus the same quarter last year. Core organic revenue growth declined 4%. Fourth quarter GAAP diluted EPS was $4.20, 5% higher versus the same quarter last year, driven by 70 basis points of operating margin expansion. Fourth quarter adjusted EPS was $5.67, 5% higher versus the same quarter last year, driven by 100 basis points of adjusted operating margin expansion. Full year revenue was $42.86 billion,
UPPSALA, Sweden, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced its unaudited financial results for the third quarter ended September 30, 2023. Highlights Third quarter 2023 revenue totaled $44.2 million, representing year over year growth of 39% on a reported basis and 38% on a constant currency adjusted like-for-like basisTotal Explore customer installations reached 87, with 13 installations during the third quarterTotal Signature Q100 placements reached 153, with 21 placements during the third quarterExplore revenue of $32.3 million accounted for 73% of total third quarter revenue, with Explore Kit revenue totaling $17.4 million, or 54
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Highlights Third quarter revenue was $10.57 billion, 1% lower versus the same quarter last year. Core organic revenue growth was 1%. Third quarter GAAP diluted earnings per share (EPS) was $4.42, 17% higher versus the same quarter last year, driven by 160 basis points of operating margin expansion. Third quarter adjusted EPS was $5.69, 12% higher versus the same quarter last year, driven by 200 basis points of adjusted operating margin expansion. The impact of the macroeconomic conditions that th
UPPSALA, Sweden, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced its unaudited financial results for the second quarter ended June 30, 2023. Highlights Second quarter 2023 revenue totaled $29.4 million, representing year over year growth of 7.0% on a reported basis and 7.2% on a constant currency adjusted like-for-like basisTotal Explore customer installations reached 74, with 11 installations during the second quarterTotal Signature Q100 placements reached 132, with 15 placements during the second quarterExplore revenue of $18.2 accounted for 62% of total second quarter revenue, with Explore Kit revenue totaling $6.0 million, or 33% of to
UPPSALA, Sweden, July 13, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced it will release financial results for the second quarter of 2023 before the market open on Wednesday, August 9, 2023. Company management will host a conference call to discuss these results at 8:00 am ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live webcast of the conference call will be available in the "Events" section of the Company's website at https://investors.olink.com/news-events/events. The webcast will be archived and available for replay for at least 90 days
UPPSALA, Sweden, May 11, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced its unaudited financial results for the first quarter ended March 31, 2023. Highlights First quarter 2023 revenue totaled $27.5 million, representing year over year growth of 21% on a reported basis and 25% on a constant currency adjusted like-for-like basisTotal Explore customer installations reached 63, with 11 installations during the first quarterTotal Signature Q100 placements reached 117, with 26 placements during the first quarterExplore revenue of $16.9 million accounted for 61% of total first quarter revenue, with Explore Kit revenue totaling $9.4 million, or 56% of t
UPPSALA, Sweden, April 17, 2023 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the "AGM") of Olink Holding AB (publ), reg. no 559189-7755, (the "Company"), on 17 April 2023 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company's website, www.olink.com. Adoption of the balance sheet and income statement, disposition regarding the Company's results and discharge from liabilityThe AGM adopted the Company's income statement and balance sheet and the consolidated income statement an
Morgan Stanley analyst Tejas Savant maintains Olink Holding (NASDAQ:OLK) with a Equal-Weight and maintains $26 price target.
Canaccord Genuity analyst Kyle Mikson reiterates Olink Holding (NASDAQ:OLK) with a Hold and maintains $26 price target.
Olink Holding (NASDAQ:OLK) reported its Q4 earnings results on Monday, March 25, 2024 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Olink Holding missed estimated earnings by -140.0%, reporting an EPS of $-0.06 versus an estimate of $0.15. Revenue was up $10.67 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.07 which was followed by a 0.0% increase in the share price the next day. Here's a look at Olink Holding's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -0.08 -0.10 -0.12 0.01 EPS Actual -0.01 -0.07 -0.11 0.05 Revenue Estimate 43.24M 33.34M 27.27M 57.30M R
Olink Holding (NASDAQ:OLK) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.15 by 140 percent. This is a 220 percent decrease over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $68.55 million which missed the analyst consensus estimate of $89.86 million by 23.71 percent. This is a 18.43 percent increase over sales of $57.88 million the same period last year.
Offer Now Scheduled to Expire at 5:00 p.m., New York Time, on January 3, 2024Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher"), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the "Buyer"), has extended the expiration time of the offering period of its previously announced tender offer (the "Offer") to acquire all of the outstanding common shares ("Shares") and all of the outstanding American Depositary Shares, each representing one Share ("ADSs" and, together with the Shares, the "Offer Securities"), of Olink Holding AB (publ) ("Olink") for $26.00 per Share and per ADS, in cash.The Offer is being made pursuant to the Purchase A
Olink Holding (NASDAQ:OLK) reported its Q3 earnings results on Wednesday, November 15, 2023 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Olink Holding beat estimated earnings by 87.5%, reporting an EPS of $-0.01 versus an estimate of $-0.08. Revenue was up $12.38 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.03 which was followed by a 1.69% increase in the share price the next day. Here's a look at Olink Holding's past performance: Quarter Q2 2023 Q1 2023 Q4 2022 Q3 2022 EPS Estimate -0.10 -0.12 0.01 -0.09 EPS Actual -0.07 -0.11 0.05 -0.01 Revenue Estimate 33.34M 27.27M 57.30M 28.96M
Olink Holding (NASDAQ:OLK) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.08) by 87.5 percent. This is unchanged from the same period last year. The company reported quarterly sales of $44.15 million which beat the analyst consensus estimate of $43.24 million by 2.12 percent. This is a 38.97 percent increase over sales of $31.77 million the same period last year.